相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
Caroline Imbert et al.
NATURE COMMUNICATIONS (2020)
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study
Reut Hadash-Bengad et al.
FRONTIERS IN ONCOLOGY (2020)
Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications
Tanner Smida et al.
FRONTIERS IN ONCOLOGY (2020)
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
Ines Pires Da Silva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
Daniel Olson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sex-associated molecular differences for cancer immunotherapy
Youqiong Ye et al.
NATURE COMMUNICATIONS (2020)
Strength of immune selection in tumors varies with sex and age
Andrea Castro et al.
NATURE COMMUNICATIONS (2020)
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
Nethanel Asher et al.
CANCERS (2020)
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Shixiang Wang et al.
MOLECULES (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers A Systematic Review and Meta-analysis
Christopher J. D. Wallis et al.
JAMA ONCOLOGY (2019)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility
Monica Marzagalli et al.
FRONTIERS IN ENDOCRINOLOGY (2016)
Sex differences in immune responses
Sabra L. Klein et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Gender Disparity and Mutation Burden in Metastatic Melanoma
Sameer Gupta et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Gender Disparity and Mutation Burden in Metastatic Melanoma
Sameer Gupta et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sex bias in trials and treatment must end
Alison M. Kim et al.
NATURE (2010)
Expression of Estrogen Receptor Alpha and Beta in Breast Cancers of Pre- and Post-menopausal Women
Blanca Murillo-Ortiz et al.
PATHOLOGY & ONCOLOGY RESEARCH (2008)
Gender differences in drug responses
Flavia Franconi et al.
PHARMACOLOGICAL RESEARCH (2007)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
分享论文
